Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of Docetaxel/Prednisone in Combination With Sargramostim as Treatment for Hormone-refractory Prostate Cancer

NCT00313482 is registered in ClinicalTrials.gov with Veeda Oncology as lead sponsor.

NCT NCT00313482
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00313482 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of Docetaxel/Prednisone in Combination With Sargramostim as Treatment for Hormone-refractory Prostate Cancer
Lead sponsor
Veeda Oncology
Phase
Phase 2
Overall status
Terminated
Start date
April 30, 2006
Completion date
August 31, 2008
Enrollment
35 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hormone refractory prostate cancer